Krishna Komanduri, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Avacta Therapeutics
    Topic:
    Oncology drug development
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Novartis
    Topic:
    Cellular therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Iovance
    Topic:
    Cellular therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Optum Health
    Topic:
    Oncology treatment pathways
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    CRISPR Therapeutics
    Topic:
    Cellular therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Cargo Therapeutics
    Topic:
    Cellular Therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Cellular Therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Type of financial relationship:
    Independent contractor
    Ineligible company:
    Incyte
    Topic:
    Graft vs. Host Disease
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Roche
    Topic:
    T cell engager therapy
    Date added:
    04/21/2023
    Date updated:
    04/21/2023
Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes